Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD Study of Ziresovir in Healthy Subjects
NCT04788017Phase 1Completed
- Sponsor
- Ark Biosciences
- Start
- Mar 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ziresovir in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Ark Biosciences. Primary endpoints: Numbers of all Adverse Events, Percentages of all Adverse Events and 9 more. Started Mar 2021; status: completed.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT04788017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04788017.